Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
News Feb 17, 2009
Epeius Biotechnologies Corporation has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body.
With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.
Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent Rexin-G®—the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of biological anti-cancer agents that are highly selective for diseased tissues is currently in clinical development.
Anti-cancer agents such as Rexin-G® can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.